Multiple techniques are available to study failure of neuromuscular transmission. Electrophysiological techniques used in patients are well suited to detect failure of neuromuscular transmission; however, these methods offer little insight into the mechanisms underlying failure of transmission. More detailed techniques that are better suited for studying the underlying mechanisms can be performed in animal models of neuromuscular disease. However, it is often difficult to compare studies using different techniques to measure neuromuscular transmission. In this review, I discuss different techniques that are available to study failure of neuromuscular transmission. The strengths and weaknesses of various techniques are compared using several diseases as examples. The review concludes with a discussion of mechanisms that may contribute to failure of neuromuscular transmission during repetitive stimulation.
Balice-Gordon RJ, Smith DB, Goldman J.Cork LC, Shirley A, Cope TC, Pinter MJ. 2000. Functional motor unit failure precedes neuromuscular degeneration in canine motor neuron disease. Ann Neurol47:596–605.
2.
Barstad JA, Lilleheil G.1968. Transversaly cut diaphragm preparation from rat. An adjuvant tool in the study of the physiology and pharmacology of the myoneural junction. Arch Int Pharmacodyn Ther175:373–390.
3.
Boyd IA, Martin AR. 1956. The end-plate potential in mammalian muscle. J Physiol132:74–91.
4.
Cull-Candy SG, Miledi R.Trautmann A.1978. Acetylcholine-induced channels and transmitter release at human endplates. Nature271:74–75.
5.
Drachman DB. 1994. Myasthenia gravis. N Engl J Med330:1797– 810.
6.
Elmqvist D.Hofmann WW, Kugelberg J, Quastel DM. 1964. An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J Physiol174:417–434.
7.
Elmqvist D.Lambert EH. 1968. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc43:689–713.
8.
Engisch KL, Rich MM, Cook N.Nowycky MC. 1999. Lambert-Eaton antibodies inhibit Ca2+ currents but paradoxically increase exocytosis during stimulus trains in bovine adrenal chromaffin cells. J Neurosci19:3384–3395.
9.
Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, and others. 2004. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol185:232–240.
10.
Frey D.Schneider C, Xu L, Borg J, Spooren W, Caroni P. 2000. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci20:2534–2542.
11.
Giovannini F.Sher E, Webster R, Boot J, Lang B.2002. Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodiesaffected neuromuscular junctions. Br J Pharmacol136:1135–1145.
12.
Glavinovic MI. 1979a. Presynaptic action of curare. J Physiol290:499– 506.
13.
Glavinovic MI. 1979b. Voltage clamping of unparalysed cut rat diaphragm for study of transmitter release. J Physiol290:467–480.
14.
Gooch JL. 1995. AAEM case report #29: prolonged paralysis after neuromuscular blockade. Muscle Nerve18:937–942.
15.
Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, and others. 1994. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science264:1772–1775.
16.
Hamilton BR, Smith DO. 1991. Autoreceptor-mediated purinergic and cholinergic inhibition of motor nerve terminal calcium currents in the rat. J Physiol432:327–341.
17.
Hille B.2001. Ion channels of excitable membranes. 3rd ed.Sunderland, MA: Sinauer Associates.
Katz E.Ferro PA, Weisz G, Uchitel OD. 1996. Calcium channels involved in synaptic transmission at the mature and regenerating mouse neuromuscular junction. J Physiol497(Pt 3):687–697.
20.
Kennel PF, Finiels F.Revah F.Mallet J. 1996. Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic study. Neuroreport7:1427–1431.
21.
Kimura J.2001. Electrodiagnosis in diseases of nerve and muscle: principles and practice. 3rd ed.New York: Oxford University Press.
22.
Lomo T.Rosenthal J. 1972. Control of ACh sensitivity by muscle activity in the rat. J Physiol221:493–513.
23.
Lundberg A.Quilisch H. 1953. On the effect of calcium on presynaptic potentiation and depression at the neuro-muscular junction. Acta Physiol Scand Suppl111:121–129.
24.
Magleby KL, Pallotta BS. 1981. A study of desensitization of acetylcholine receptors using nerve-released transmitter in the frog. J Physiol316:225–250.
25.
Malinowski MN, Cannady SB, Schmit KV, Barr PM, Schrock JW, Wilson DF. 1997. Adenosine depresses transmitter release but is not the basis for ‘tetanic fade’ at the neuromuscular junction of the rat. Neurosci Lett230:81–84.
26.
Otis T.Zhang S, Trussell LO. 1996. Direct measurement of AMPA receptor desensitization induced by glutamatergic synaptic transmission. J Neurosci16:7496–7504.
27.
Pennefather P.Quastel DM. 1982. Fast desensitization of the nicotinic receptor at the mouse neuromuscular junction. Br J Pharmacol77:395–404.
28.
Person RS, Kudina LP. 1972. Discharge frequency and discharge pattern of human motor units during voluntary contraction of muscle. Electroencephalogr Clin Neurophysiol32:471–483.
29.
Pinter MJ, Cope TC, Cork LC, Green SL, Rich MM. 2001. Canine motor neuron disease: a view from the motor unit. In: Cope TC, editor. Motor neurobiology of the spinal cord. New York: CRC Press. p 231–250.
30.
Pinter MJ, Waldeck RF, Cope TC, Cork LC. 1997. Effects of 4-aminopyridine on muscle and motor unit force in canine motor neuron disease. J Neurosci17:4500–4507.
31.
Plomp JJ, Van Kempen GT, De Baets MB, Graus YM, Kuks JB, Molenaar PC. 1995. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol37:627–636.
32.
Plomp JJ, van Kempen GT, Molenaar PC. 1992. Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha-bungarotoxin-treated rats. J Physiol458:487–499.
33.
Preston DC, Shapiro BE. 1998. Electromyography and neuromuscular disorders: clinical-electrophysiologic correlations. Boston: Butterworth-Heinemann.
34.
Redman RS, Silinsky EM. 1993. A selective adenosine antagonist (8-cyclopentyl-1,3-dipropylxanthine) eliminates both neuromuscular depression and the action of exogenous adenosine by an effect on A1 receptors. Mol Pharmacol44:835–840.
35.
Rich MM, Bird SJ, Raps EC, McCluskey LF, Teener JW. 1997. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve20:665–673.
36.
Rich MM, Colman H.Lichtman JW. 1994. In vivo imaging shows loss of synaptic sites from neuromuscular junctions in a model of myasthenia gravis. Neurology44:2138–2145.
37.
Rich MM, Teener JW, Raps EC, Schotland DL, Bird SJ. 1996. Muscle is electrically inexcitable in acute quadriplegic myopathy [see Comments]. Neurology46:731–736.
38.
Rich MM, Wang X.Cope TC, Pinter MJ. 2002. Reduced neuromuscular quantal content with normal synaptic release time course and depression in canine motor neuron disease. J Neurophysiol88:3305–3314.
39.
Robitaille R.Charlton MP. 1992. Presynaptic calcium signals and transmitter release are modulated by calcium-activated potassium channels. J Neurosci12:297–305.
40.
Ruff RL, Lennon VA. 1998. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann Neurol43:370–379.
41.
Sanders DB. 2003. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci998:500–508.
42.
Santafe MM, Salon I.Garcia N, Lanuza MA, Uchitel OD, Tomas J. 2003. Modulation of ACh release by presynaptic muscarinic autoreceptors in the neuromuscular junction of the newborn and adult rat. Eur J Neurosci17:119–127.
43.
Snider WD, Harris GL. 1979. A physiological correlate of disuse-induced sprouting at the neuromuscular junction. Nature281:69–71.
44.
Stalberg E.Schwartz MS, Trontelj JV. 1975. Single fibre electromyography in various processes affecting the anterior horn cell. J Neurol Sci24:403–415.
45.
Takamori M.Sakato S, Okumura S. 1984. Presynaptic function modified by acetylcholine-receptor interaction in experimental autoimmune myasthenia gravis. J Neurol Sci66:245–253.
46.
Tsujimoto T.Umemiya M, Kuno M. 1990. Terminal sprouting is not responsible for enhanced transmitter release at disused neuromuscular junctions of the rat. J Neurosci10:2059–2065.
47.
Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, and others. 2003. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci998:324–335.
48.
Wang X.Engisch KL, Li Y, Pinter MJ, Cope TC, Rich MM. 2004. Decreased synaptic activity shifts the calcium dependence of release at the mammalian neuromuscular junction in vivo. J Neurosci24:10687–10692.
49.
Wood SJ, Slater CR. 2001. Safety factor at the neuromuscular junction. Prog Neurobiol64:393–429.
50.
Xu J.Wu LG. 2005. The decrease in the presynaptic calcium current is a major cause of short-term depression at a calyx-type synapse. Neuron46:633–645.
